Tracon Pharmaceuticals

TRACON Pharma releases TRC105 phase II results for recurrent glioblastoma

Monday, February 13, 2017

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, has reported top-line results from a randomized phase II clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). 

[Read More]

Santen, Tracon ink ophthalmology agreement

Wednesday, March 5, 2014

Tracon Pharmaceuticals and Santen Pharmaceutical have entered into an exclusive agreement for the development and global commercialization of Tracon’s anti-endoglin antibodies, including TRC105, in ophthalmology. Preclinical and clinical data from Tracon’s ongoing development of TRC105, in combination with anti-VEGF products in oncology, indicate inhibiting both the endoglin and VEGF pathways has the potential to show advantages over inhibiting VEGF alone in the treatment of conditions such as wet age-related macular degeneration (wet AMD).

[Read More]